Compare Invesco DB Agriculture Fund (DBA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Johnson & Johnson — how do they compare? Invesco DB Agriculture Fund trades at $28.33 (market cap $1.32B), while Johnson & Johnson trades at $261.43 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 468.3× Invesco DB Agriculture Fund's market cap, and Johnson & Johnson pays a 2.09% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Johnson & Johnson for 129 Days on average.
| DBA | JNJ | |
|---|---|---|
Market Cap | $1.32B | $618.09B |
Volume | 771,657 | 6,050,983 |
52-Week High | $29.49 | $278.43 |
52-Week Low | $25.44 | $186.00 |
Typical Hold Time | 24 Days | 129 Days |
Sector | — | Health |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.33, down 0.56% with a bearish technical signal from moving averages. The ETF has returned 12.4% year-to-date, closely tracking the S&P 500, supported by agricultural commodity strength from weather risks and geopolitical tensions. Recent news highlights consolidation near all-time highs with a 3.25% yield, though the 0.85% expense ratio remains a concern.
Outlook remains mixed with bullish agricultural fundamentals offset by high fees and commodity volatility. Key catalysts include Trump-Xi geopolitical developments and El Niño weather patterns, while risks involve commodity price swings and expense drag. The neutral oscillator signals suggest near-term consolidation around current levels.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
